Drug packaging and delivery using perfluorocarbon nanoparticles for targeted inhibition of vascular smooth muscle cells

Acta Pharmacologica Sinica

Volumn 30, Issue 11, 2009, Pages 1577-1584

  Zhou, Zhao Xiong ^a   Zhang, Bai Gen ^a   Zhang, Hao ^a   Huang, Xiao Zhong ^a   Hu, Ya Li ^a   Sun, Li ^b   Wang, Xiao Min ^b   Zhang, Ji Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Department of Pharmacy ^*  (China)

Author keywords

Fluorocarbons; Nanoparticles; Restenosis; Smooth muscle cells; Sustained release

Indexed keywords

DEXAMETHASONE ACETATE; DEXAMETHASONE ACETATE PLUS PERFLUOROCARBON NANOPARTICLE; DEXAMETHASONE PHOSPHATE PLUS PERFLUOROCARBON NANOPARTICLE; DEXAMETHASONE SODIUM PHOSPHATE; FLUOROCARBON; NANOCAPSULE; NANOPARTICLE; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANALYZER; ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PACKAGING; DRUG SOLUBILITY; DRUG TARGETING; FLOW CYTOMETRY; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LASER; MICROMORPHOLOGY; NANOENCAPSULATION; NANOPHARMACEUTICS; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SMOOTH MUSCLE FIBER; SUSTAINED DRUG RELEASE; UMBILICAL ARTERY; VASCULAR SMOOTH MUSCLE; ZETA POTENTIAL;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUOROCARBONS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NANOPARTICLES; PARTICLE SIZE; UMBILICAL ARTERIES;

EID: 70449370064     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.146     Document Type: Article

References (29)

1. Schainfeld RM. Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature. Catheter Cardiovasc Interv 2002; 56: 421-431
2. Shah PB, Lilly CM. Interventional therapy for coronary artery disease. Am J Respir Crit Care Med 2002; 166: 791-796
3. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-2273
4. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, et al. Sustained reduction of instent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002; 106: 1195-1198
5. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, et al. Paclitaxeleluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670
6. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005; 68: 483-492
7. Patti G, Pasceri V, Carminati P, D'Ambrosio A, Carcagnì A, Di Sciascio G. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2005; 95: 502-505
8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
9. Harald Vik-Mo, Rune W, Knut H. Coronar y aneur ysm af ter implantation of a paclitaxel-eluting stent. Scandinavian Cardiovasc J 2004; 38: 349-352
10. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2: 297-310.
11. Lanza GM, Winter P, Caruthers S, Schmeider A, Crowder K, Morawski A, et al. Novel paramagnetic pontrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol 2004; 5: 495-507.
12. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 2002; 106: 2842-2847
13. Dong YC, Feng SS. Methoxy poly (ethylene glycol)-poly(lactide) (MPEGPLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004; 25: 2843-2849
14. Gallicchio M, Argyriou S, Ianches G, Filonzi EL, Zoellner H, Hamilton JA, et al. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1994; 14: 815-823
15. Cordelier P, Esteve JP, Rivard N, Marletta M, Vaysse N, Susini C, et al. The activation of neuronal NO synthase is mediated by G-protein âã subunit and the tyrosine phosphatase SHP-2. FASEB 1999: 132037-132050
16. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F, et al. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res 2001; 89: 772-778
17. Mayr M, Li C, Zou Y, Huemer U, Hu Y, Xu Q. Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases. FASEB 2000; 14: 261-270
18. Wickline SA, Lanza GM. Nanotechnology for molecular imaging and targeted therapy. Circulation 2003; 107: 1092-1095
19. Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, et al. Minute dosages of ávâ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB2008; 22: 2758-2767
20. Nihant N, Grandfiles C, Jerome R, Teyssie P. Microencapsulation by coacervation of poly (lactid-co-glycolide), IV: effect of the processing parameters on coacervation and encapsulation. J Control Release 1995; 35:117-125
21. Song CX, Labhasetwar V, Cui XM, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Control Release 1998; 54: 201-211
22. Guzman LA, Labhasetwar V, Song CX, Jang YS, Lincoff AM, Levy R, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996; 94: 1441-1448
23. Lanza GM, Abendschein DR, Hall CS, Marsh JN, Scott MJ, Scherrer DE, et al. Molecular imaging of stretch induced tissue factor expression in carotid arteries with intravascular ultrasound. Invest Radiol 2000; 35: 227-234
24. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin deliver: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008; 29: 1094-1102
25. Kima J, Chauhan A. Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. Int J Pharm 2008; 2: 205-222
26. Kim Dong-Hwan, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterial 2006; 27: 3031-3037
27. Zweersa LT, Engbersa HM, Grijpmaa DW, Feijen J. Release of antirestenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. J Control Release 2006; 114: 317-324
28. Cleek RL, Rege AA, Denner LA, Eskin SG, Mikos AG. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly (DL-lactic-co-glycolic acid) microparticles. J Biomed Mater Res 1998; 35: 525-530
29. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711